Johnson & Johnson is assuming full responsibility for the manufacturing of a drug substance for its Covid-19 vaccine at Emergent BioSolutions Inc.’s Bayview facility, the company said in a statement.

It will add dedicated leaders for operations and quality, and “significantly” increase the number of manufacturing, quality and technical operations personnel at the site, according to the statement.

• GK Energy Rallies on Rs 235.92 Crore Solar Pump Order
• Cupid Hits Fresh 52-Week High on Rs 128 Crore Block Deal
• Ather Energy Slips Despite $200 Million Fundraise Buzz
• Shyam Metalics Slips Even as Q1 Volumes Surge
• Unihealth Hospitals Shares Hit 5% Upper Circuit on Plans to Raise Stake 

The company will work closely with the Food and Drug Administration for the emergency use authorization of the specific facility, adding that all its doses so far have met regulatory quality standards. The company said it expects to deliver almost 100 million doses of the Covid-19 vaccine to the US government by the end of May.